Construction and application of the human glioblastoma cell line Y1203

doi:10.3969/j.issn.1006-7795.2023.05.005

Abstract

Abstract: Objective To establish a glioblastoma cell line, Y1203, with stem cell-like phenotypes for the study of tumor cell stemness maintenance and potential mechanisms of treatment resistance. Methods Y1203 cells were derived from tumor tissue obtained by recurrent resection in a 49-year-old female glioblastoma patient. Y1203 cells were used to establish patient-derived tumor xenograft (PDX) models both orthotopically and subcutaneously. Flow cytometry was applied to analyze the cell cycle distribution of different passages of Y1203 cells. Real-time quantitative polymerase chain reaction was performed to assess the expression of stem cell markers, including transcription factor SOX-2 (SOX2) and cluster of differentiation-44 (CD44). RNA-Seq was conducted to compare the expression profiles between Y1203 and U87 cells. Results The short tandem repeats (STR) analysis confirmed the homogeneity between Y1203 cells and the patient’s tumor tissue, and they were distinct from commonly used cell lines available in the ExPASy database. Genetic testing revealed isocitrate dehydrogenase 1 (IDH1) wild-type, telomerase reverse transcriptase (TERT) promoter mutation, B-Raf proto-oncogene (BRAF V600E) mutation, tumor protein p53 (TP53) mutation, and ATRX chromatin remodeler (ATRX) mutation. The human glioblastoma cell line Y1203 exhibited unlimited proliferation in vitro and thus orthotopic and subcutaneous glioblastoma models was successfully established. Compared to other glioma cell lines, Y1203 cells showed high expression of the tumor stem cell markers CD44 and SOX2, as well as significant enrichment of glioma stem cell-associated pathways. Conclusions The human glioblastoma cell line Y1203 shows low differentiation, high malignancy, and strong resistance to radiotherapy and chemotherapy, and it possesses glioblastoma stem cell characteristics. The establishment of Y1203 cell line provides an experimental basis for preclinical studies of glioblastoma.

Key words: glioblastoma, primary culture, stemness, patient derived tumor xenograft model

CLC Number:

Zheng Yi, Song Lairong, Xu Xiaoying, Wu Zhen, Li Xiaojie, Xie Lei, Chen Feng, Li Wenbin. Construction and application of the human glioblastoma cell line Y1203[J]. Journal of Capital Medical University, 2023, 44(5): 733-740.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.05.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I5/733

References

［1］Peng Y, Chen F, Li S, et al. Tumor-associated macrophages as treatment targets in glioma［J］. Brain Sci Adv, 2020, 6(4):306-323.
［2］舒晓宏. 胶质母细胞瘤的治疗策略［J］. 大连医科大学学报,2020,42(6):481-486.
［3］杨帆, 张剑宁. 胶质母细胞瘤免疫治疗的研究现状及进展［J］. 中国微侵袭神经外科杂志,2020,25(8):376-378.
［4］Song L, Huo X, Li X, et al. SERPINF1 mediates tumor progression and stemness in glioma［J］. Genes (Basel),2023,14(3): 580.
［5］Akter F, Simon B, de Boer N L, et al. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities［J］. Biochim Biophys Acta Rev Cancer,2021,1875(1):188458.
［6］刘小珍, 郑智国, 凌志强. 肿瘤细胞原代培养与保存［J］. 中国肿瘤,2015,24(4):276-283.
［7］刘斌. 胶质瘤干细胞通过SOX2上调CD39介导免疫逃逸的功能及机制研究［D］: 苏州：苏州大学，2022.
［8］王雅宁. 基于胶质瘤干细胞性建立的替莫唑胺耐药临床预测模型及替莫唑胺耐药细胞系的构建和特征分析［D］. 北京：北京协和医学院，2022.
［9］庞龙, 张军峰, 刘博迪, 等. 脑胶质瘤干细胞分选方法研究进展［J］. 转化医学电子杂志,2018,5(7):17-22.
［10］张永辉, 昝向阳, 李敏, 等. 免疫磁珠法分选人脑胶质瘤干细胞的体外培养及鉴定［J］. 新疆医学,2012,42(6):17-20.
［11］周瑞婷, 何桂媛, 李文新, 等. 肿瘤干细胞的分选与培养［J］. 中国组织化学与细胞化学杂志,2022,31(4):401-406.
［12］Subramanian A, Tamayo P, Mootha V K, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles［J］. Proc Natl Acad Sci U S A, 2005,102 (43): 15545-15550.
［13］郑淑荣, 庞波, 柴睿超. 第五版《世界卫生组织中枢神经系统肿瘤分类指南》下成人胶质瘤诊断及预后［J］. 生物化学与生物物理进展,2022,49(11):2192-2198.
［14］Song L, Li X, Xu X, et al. Comprehensive analysis of the prognostic value and molecular function of CRNDE in glioma at bulk and single-cell levels［J］. Cell, 2022,11(22)：3669.
［15］Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions［J］. J Exp Clin Cancer Res, 2022, 41(1):142.
［16］郑诗凡, 马皎. 肿瘤干细胞代谢在肿瘤发展中作用的研究进展［J］. 上海交通大学学报(医学版),2022,42(6):825-832.
［17］李星霓. 肿瘤干细胞的研究进展及靶向治疗［J］. 内蒙古医学杂志,2022,54(6):707-709.
［18］陆翰杰, 秦艳茹. 肿瘤干细胞在肿瘤侵袭转移中的作用机制及功能相关信号通路研究进展［J］. 山东医药,2016,56(7):94-96.

[1]	Xiao Zeru, Yan Rui, Liang Ziwei, Ge Yang, An Guangyu. Major tobacco carcinogen benzo(a)pyrene induces infiltration of M2 type macrophages by upregulating cyclooxygenase-2 expression in esophageal squamous carcinoma [J]. Journal of Capital Medical University, 0, (): 753-761.
[2]	Tan Yubo, Suboyinuer Tuerhong, Huang Jing, Zhang Tingting, Liu Junjie, Shaya Mahati. The mechanism of miR-150 targeted regulation of IGF2BP2 on the malignant phenotype of liver cancer [J]. Journal of Capital Medical University, 2023, 44(5): 762-767.
[3]	Yu Jianyu, Zheng Yi, Li Wenbin. Bioinformatics analysis of hippocalcin like 1 expression and clinical prognosis in primary central nervous system lymphoma [J]. Journal of Capital Medical University, 2023, 44(5): 724-732.
[4]	Liu Xiu, Li Wencai. Preliminary study on the effect of UNC0379 on the proliferation of glioma cells [J]. Journal of Capital Medical University, 2023, 44(5): 741-746.
[5]	Peng Yichen, Zheng Yi, Li Shenglan, Yu Jianyu, Lan Yanjie, Liu Xinrui, Chen Feng, Li Wenbin. Study of genes associated with aberrant methylation regulation in high-grade meningiomas [J]. Journal of Capital Medical University, 2023, 44(5): 747-752.
[6]	Yin Xue, Yu Minghang, Wang Xi, Chen Jinglong. Progresses on the mutation of SWI/SNF complex and its impact on immune checkpoint inhibitor therapy response in hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 768-774.
[7]	Yin Shuo, Chen Feng, Zheng Xiaohong, Zhang Weichunbai, Li Wenbin. Novel drug therapies promote the treatment progress of primary central nervous system lymphoma [J]. Journal of Capital Medical University, 2023, 44(5): 775-781.
[8]	Wan Yan, Liu Fang, Guo Shan, Wu Jian. Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 811-820.
[9]	Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer [J]. Journal of Capital Medical University, 2023, 44(5): 882-888.
[10]	Ning Tingting, Wang Zhaoqing, Zhang Nan, Zhu Shengtao. Clinical importance of ACE2 expression in colon cancer and susceptibility of colon cancer cells to three human coronaviruses using ACE2 as their receptor [J]. Journal of Capital Medical University, 2023, 44(4): 663-668.
[11]	. Oncologic and functional outcomes after laparoscopic radical prostatectomy:10-years follow-up [J]. Journal of Capital Medical University, 2023, 44(3): 424-432.
[12]	Zhu Guangyi, Wang Runjin, Xiong Tianyu, Ye Xiaobo, Liu Zhanliang, Cao Fang, Lin Zhemin, Niu Yinong. Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 433-438.
[13]	Wang Runjin, Ye Xiaobo, Zhang Yudong, Zhu Guangyi, Yang Kun, Niu Yinong. Effect of different invasion patterns on the prognosis of patients with T3a renal cell carcinoma [J]. Journal of Capital Medical University, 2023, 44(3): 439-448.
[14]	Zhang Yudong, Wei Houyi, Wang Runjin, Jiang Mingxin, Yang Kun, Wang Mingshuai, Wasilijiang Wahafu, Song Liming, Jin Mulan, Xing Nianzeng, Niu Yinong. Prognostic significance of the controlling nutritional status (CONUT) score in patients with bladder cancer treated with radical cystectomy and ileal conduit [J]. Journal of Capital Medical University, 2023, 44(3): 449-456.
[15]	Xiong Tianyu, Niu Yinong. Mechanism of periprostatic adipose tissue affecting the development of prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 457-462.